Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Increased heat shock protein 70 (Hsp70) serum levels and low NK cell counts after radiotherapy - potential markers for predicting breast cancer recurrence?

Rothammer A, Sage EK, Werner C, Combs SE, Multhoff G.

Radiat Oncol. 2019 May 10;14(1):78. doi: 10.1186/s13014-019-1286-0.

2.

Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.

Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, Guppy N, Borg E, Falzon M, Nankivell M, Nicholson AG, Janes SM.

Lung Cancer. 2019 Jan;127:164-166. doi: 10.1016/j.lungcan.2018.12.004. Epub 2018 Dec 5.

PMID:
30642545
3.

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S, Michaut M, Williams S, Barthorpe S, Lightfoot H, Busacca S, Sharkey A, Yuan Z, Sage EK, Vallath S, Le Quesne J, Tice DA, Alrifai D, von Karstedt S, Montinaro A, Guppy N, Waller DA, Nakas A, Good R, Holmes A, Walczak H, Fennell DA, Garnett M, Iorio F, Wessels L, McDermott U, Janes SM.

Elife. 2018 Jan 18;7. pii: e30224. doi: 10.7554/eLife.30224.

4.

Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients.

Sage EK, Schmid TE, Geinitz H, Gehrmann M, Sedelmayr M, Duma MN, Combs SE, Multhoff G.

Strahlenther Onkol. 2017 Aug;193(8):648-655. doi: 10.1007/s00066-017-1144-7. Epub 2017 May 12.

PMID:
28500490
5.

Genetically modified mesenchymal stromal cells in cancer therapy.

Sage EK, Thakrar RM, Janes SM.

Cytotherapy. 2016 Nov;18(11):1435-1445. doi: 10.1016/j.jcyt.2016.09.003. Review.

6.

Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy.

Yuan Z, Lourenco Sda S, Sage EK, Kolluri KK, Lowdell MW, Janes SM.

Cytotherapy. 2016 Jul;18(7):860-9. doi: 10.1016/j.jcyt.2016.04.005.

7.

Combined cell-gene therapy for lung cancer: rationale, challenges and prospects.

Thakrar RM, Sage EK, Janes SM.

Expert Opin Biol Ther. 2016 Jul;16(7):853-7. doi: 10.1080/14712598.2016.1188074. Epub 2016 Jun 3. No abstract available.

PMID:
27248673
8.

CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity.

Vallath S, Sage EK, Kolluri KK, Lourenco SN, Teixeira VS, Chimalapati S, George PJ, Janes SM, Giangreco A.

Sci Rep. 2016 Apr 1;6:24006. doi: 10.1038/srep24006.

9.

Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients.

Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, Combs SE, Multhoff G.

Radiother Oncol. 2016 Jan;118(1):176-80. doi: 10.1016/j.radonc.2015.11.016. Epub 2015 Dec 9.

PMID:
26683801
10.

Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.

Yuan Z, Kolluri KK, Sage EK, Gowers KH, Janes SM.

Cytotherapy. 2015 Jul;17(7):885-96. doi: 10.1016/j.jcyt.2015.03.603. Epub 2015 Apr 14.

11.

Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.

Lathrop MJ, Sage EK, Macura SL, Brooks EM, Cruz F, Bonenfant NR, Sokocevic D, MacPherson MB, Beuschel SL, Dunaway CW, Shukla A, Janes SM, Steele C, Mossman BT, Weiss DJ.

Cancer Gene Ther. 2015 Jan;22(1):44-54. doi: 10.1038/cgt.2014.68. Epub 2014 Dec 19.

PMID:
25525034
12.

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.

Sage EK, Kolluri KK, McNulty K, Lourenco Sda S, Kalber TL, Ordidge KL, Davies D, Gary Lee YC, Giangreco A, Janes SM.

Thorax. 2014 Jul;69(7):638-47. doi: 10.1136/thoraxjnl-2013-204110. Epub 2014 Feb 24.

13.

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.

Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL.

J Breast Cancer. 2012 Sep;15(3):273-82. doi: 10.4048/jbc.2012.15.3.273. Epub 2012 Sep 28.

14.

β-Catenin determines upper airway progenitor cell fate and preinvasive squamous lung cancer progression by modulating epithelial-mesenchymal transition.

Giangreco A, Lu L, Vickers C, Teixeira VH, Groot KR, Butler CR, Ilieva EV, George PJ, Nicholson AG, Sage EK, Watt FM, Janes SM.

J Pathol. 2012 Mar;226(4):575-87. doi: 10.1002/path.3962. Epub 2012 Jan 17.

15.

TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population.

Loebinger MR, Sage EK, Davies D, Janes SM.

Br J Cancer. 2010 Nov 23;103(11):1692-7. doi: 10.1038/sj.bjc.6605952. Epub 2010 Nov 9.

16.

The role of bone marrow-derived stem cells in lung regeneration and repair.

Sage EK, Loebinger MR, Polak J, Janes SM.

StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute; 2008-.
2008 Sep 30.

17.

Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia.

Sage EK, Noursadeghi M, Evans HE, Parker SJ, Copas AJ, Edwards SG, Miller RF.

Int J STD AIDS. 2010 Apr;21(4):288-92. doi: 10.1258/ijsa.2010.009551.

PMID:
20378904
18.

Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole.

Fisk M, Sage EK, Edwards SG, Cartledge JD, Miller RF.

Int J STD AIDS. 2009 Sep;20(9):652-3. doi: 10.1258/ijsa.2009.008470.

PMID:
19710343
19.

Mesenchymal stem cells as vectors for lung disease.

Loebinger MR, Sage EK, Janes SM.

Proc Am Thorac Soc. 2008 Aug 15;5(6):711-6. doi: 10.1513/pats.200801-009AW. Review.

Supplemental Content

Support Center